Real-world outcomes after Mirvetuximab Soravtansine treatment for recurrent ovarian Cancer: Results from a university setting
Anna V Jones, Rachel L Furuya, L Stewart Massad, Dong Wang, Mary M Mullen, Brooke E Sanders · 2026
Read Real-world outcomes after Mirvetuximab Soravtansine treatment for recurrent ovarian Cancer: Results from a university setting by Anna V Jones, Rachel L Furuya, L Stewart Massad, Dong Wang, Mary M Mullen, Brooke E Sanders (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13571410.txt.
Description
Anna Jones and co-authors report real-world results for a targeted ovarian cancer drug in a 2026 study. Mirvetuximab soravtansine is an antibody-drug conjugate that homes to folate receptor alpha, found on most ovarian cancers, and delivers its payload there. Trials showed good results under strict entry rules. This review covered sixty-six patients treated for recurrent disease at one university cancer center and its partner hospital between late 2022 and spring 2025.
Survival with and without progression was charted, and side effects catalogued from the records. Adjusted models hunted for traits tied to longer survival. Real-world cohorts include the frailer patients trials skip, so these numbers tell oncologists what to expect in the clinic.
Catalog record
| CREATOR | Anna V Jones, Rachel L Furuya, L Stewart Massad, Dong Wang, Mary M Mullen, Brooke E Sanders |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |